IMMU - Immunomedics, Inc.
| Previous Close | 15.30 |
| Open | 15.27 |
| Bid | 14.92 x 1000 |
| Ask | 15.19 x 2200 |
| Day's Range | 14.83 - 15.42 |
| 52 Week Range | 11.55 - 26.99 |
| Volume | 2,089,445 |
| Avg. Volume | 2,725,123 |
| Market Cap | 2.86B |
| Beta (3Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.88 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.30 |
- TipRanks•17 days ago
3 Hot Insider Trading Stocks To Boost Your Portfolio
Actions speak louder than words, as the saying goes. And when it comes to insiders, that certainly seems to be the case. If we track informative insider buy transactions, we can get an idea of the stocks that insiders see as compelling investing opportunities right now. As insiders have access to a wealth of company information, these insights can be very valuable when deciding which stocks to buy or sell. With that in mind we took a closer look at three stocks insiders are snapping up right now: Immunomedics (IMMU)Immunomedics focuses on the development of antibody-drugs for the treatment of cancer. Most notably sacituzumab has received Breakthrough Therapy designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who failed previous therapies. It’s also granted the drug fast track designation for lung cancer treatment. Shares have surged 12% in the last five days, and that’s partly down to an influx of insider money. Most notably, corporate director and owner venBio Select Advisor LLC recently picked up a whopping $13.5 million worth of stock. That brings venBio’s total holding of IMMU to just over $298 million. And it’s not just insiders that are bullish. The stock also shows a ‘Strong Buy’ analyst consensus with an average price target of $23- indicating that further upside potential of 54% lies ahead. “As we expect sacituzumab to address a major unmet need in the treatment of r/r mTNBC [metastatic triple negative breast cancer] next year, we continue to think that IMMU is undervalued for its potential” comments Cowen & Co analyst Phil Nadeau. “We continue to expect sacituzumab will become a standard mTNBC treatment upon its approval” the analyst added. He notes that Daiichi’s DS-1062a has the potential to be long-term competition to IMMU's sacituzumab- but reassures investors that IMMU is clearly well ahead. “Given sacituzumab's several-year lead, it will be incumbent upon DS-1062a to show meaningful advantages in order to displace it” the analyst writes. Fastly Inc (FSLY)Cloud computing services provider Fastly is a newcomer to the markets. The company, which helps companies deliver online content more quickly, debuted on the NYSE back in May. Its IPO was a great success; the company sold 11.25 million shares at $16 each, bringing returns of $180 million. Since the IPO shares have surged to the current price of $20.55.And now we can see that insiders are already pouring more money into this fast-growing tech stock. Abdiel Capital Management, one of the company’s owners, has just picked up a further $7.62 million of FSLY stock. This brings the total holding to $78.8 million. No doubt this move would make sense to five-star analyst Brad Reback of Stifel Nicolaus. He initiated coverage of the stock with a buy rating and $25 price target (22% upside potential). The analyst contends: “In the coming years, we believe Fastly can leverage its superior technological approach to drive continued strong net new customer additions and expand its wallet share among its existing installed base.” Combined with a large market opportunity and the ability to further penetrate international markets, Reback is confident that Fastly can sustain at least a 30% top-line growth profile. Myovant Sciences (MYOV)Myovant Sciences is a clinical-stage biopharma developing therapies for women’s health and endocrine diseases. Shares have crashed 47% year-to-date, with the selloff prompted by the release of relugolix phase 3 uterine fibroids data. Investors are concerned about Abbvie’s (ABBV) uterine fibroid rival, Orlissa.However, insiders are demonstrating their confidence in the company. In the last three months insiders have bought a whopping $160 million of shares. That includes a $45,000 purchase from director Sebelius Kathleen, as well as $20 million from owner Viking Global Investors. Indeed, all ten transactions in the last month are positive insider buy transactions- with only one insider sell transaction recorded four months ago.Furthermore, the Street is also staying onside. All five analysts covering the stock rate Myovant a ‘buy.’ That gives the stock its ‘Strong Buy’ analyst consensus. Meanwhile their average price target of $26 indicates massive upside potential of 194%. Analysts argue that the stock looks oversold at current levels, with Barclays analyst Geoffrey Meacham saying he still believes Myovant’s relugolix has a favorable profile compared to rival offerings. Meanwhile five-star Evercore ISI analyst Ravi Mehrotra is anticipating revenues of $944M for relugolix by 2023 due to its "commercial advantage of a one-a-day pill." Discover more Hot Insider Trading Stocks here
- Simply Wall St.•18 days ago
Are Insiders Buying Immunomedics, Inc. (NASDAQ:IMMU) Stock?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- Benzinga•21 days ago
Notable Insider Buys This Past Week: AbbVie, MGM and More
Health care companies featured prominently in the week's insider purchases. MGM Resorts International (NYSE: MGM) had a director continue to make indirect share purchases this past week. MGM stock rose about 2% in the past week, while the S&P 500 was essentially flat.
- Benzinga•last month
Notable Insider Buys This Past Week: American Airlines, MGM and More
Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. MGM Resorts International (NYSE: MGM) saw a director making indirect share purchases this past week.
- GlobeNewswire•2 months ago
Immunomedics to Participate in Upcoming Healthcare Conferences
Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.
- TheStreet.com•2 months ago
2 Biotech Names See Directors Direct Cash to Their Shares
The market suffered a sharp selloff on Monday as China announced new tariffs effective June 1 on $60 billion of imports from the U.S. That action was response to the Trump administration's decision the previous week to raise tariffs from 10% to 25% on $200 billion of imports from China after the Chinese delegation reneged on several key provisions of a new trade deal. The administration did mend fences on the trade front elsewhere to bring its full attention to bear on China. In addition, aluminum and steel tariffs on Canada were dropped.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of IMMU earnings conference call or presentation 9-May-19 12:00pm GMT
Q1 2019 Immunomedics Inc Earnings Call
- Associated Press•2 months ago
Immunomedics: 1Q Earnings Snapshot
The Morris Plains, New Jersey-based company said it had a loss of 46 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•2 months ago
Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update
Agreement with Janssen Established to Co-Promote Balversa Sacituzumab Govitecan Licensed to Everest Medicines for Greater China and Certain Asian Countries Resubmission of.
- GlobeNewswire•2 months ago
Immunomedics To Participate In Upcoming Healthcare Conferences
Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at these conferences.
- GlobeNewswire•3 months ago
Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Thursday, May 9, 2019 at 8:00 a.m. Eastern Time to discuss financial results for the first quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.
- CNBC•3 months ago
Stocks making the biggest moves midday: Disney, Restaurant Brands, Gardner Denver, Target & more
These are the stocks posting the largest moves midday Monday.
- GlobeNewswire•3 months ago
Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC) and Everest Medicines II Limited (“Everest Medicines”), a C-Bridge Capital-backed biopharmaceutical company, today announced an exclusive license agreement to develop, register, and commercialize sacituzumab govitecan in Greater China, South Korea and certain Southeast Asian countries (Territory). “We are pleased to be partnering with Everest Medicines to commercialize sacituzumab govitecan in the Asian market outside Japan and further develop the product in solid tumor indications of high unmet need in the territory,” said Usama Malik, Chief Financial Officer and Chief Business Officer of Immunomedics.
- GlobeNewswire•3 months ago
Immunomedics Announces Departure of Chief Medical Officer
“I am proud to have been part of Immunomedics and have full confidence in the capabilities of the team to bring sacituzumab govitecan to patients in a timely manner and help patients with difficult-to-treat cancers across the U.S. and the world. My decision comes after careful consideration and is driven by my personal priorities and a desire to be close to my family after many years of having worked far away from home,” commented Dr. Rob Iannone. Behzad Aghazadeh, Executive Chairman of Immunomedics, commented, “We thank Rob for his service to the Company, and wish him well in his new endeavors.
- Zacks•3 months ago
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
- Insider Monkey•3 months ago
Is Immunomedics, Inc. (IMMU) A Good Stock To Buy?
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
- Simply Wall St.•3 months ago
Is Immunomedics, Inc. (NASDAQ:IMMU) Trading At A 34% Discount?
Today we will run through one way of estimating the intrinsic value of Immunomedics, Inc. (NASDAQ:IMMU) by taking the expected future cash flows and discounting them to their present value. I will be using the Discounted Cash...
- GlobeNewswire•3 months ago
Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S.
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it has entered into a promotion agreement in which Immunomedics will provide detailing services to Janssen Biotech Inc. (Janssen), for erdafitinib in the U.S. “We are delighted to be collaborating with Janssen and we look forward to working closely with the Janssen team to help promote erdafitinib," said Brendan Delaney, Chief Commercial Officer of Immunomedics.
- Market Realist•4 months ago
Why Analysts Reduced Target Price of Immunomedics
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 25.69% for Immunomedics (IMMU) based on the company’s closing price on
- GlobeNewswire•4 months ago
Immunomedics Appoints Barbara G. Duncan to Board of Directors
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the appointment of Barbara G. Duncan to the Company’s Board of Directors and as the Chairperson of the Audit Committee. Ms. Duncan has over 30 years of financial leadership experience, of which 17 are in the life sciences industry. “We are honored to have Barbara join our Board.
- GlobeNewswire•5 months ago
Immunomedics to Participate in Cowen and Company 39th Annual Health Care Conference
Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in a fireside chat at Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 2:10 p.m. Eastern Time at the Boston Marriott Copley Place, Boston, MA. A live audio webcast of the presentation will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with institutional investors at the conference.
- GlobeNewswire•5 months ago
Research Report Identifies Axalta Coating, The Home Depot, Immunomedics, Kosmos Energy, Casa, and Ormat Technologies with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of IMMU earnings conference call or presentation 25-Feb-19 10:00pm GMT
Q2 2019 Immunomedics Inc Earnings Call
- GlobeNewswire•5 months ago
Lawsuit for Investors in NASDAQ: IMMU shares against Immunomedics, Inc. announced by Shareholders Foundation
SAN DIEGO, Feb. 26, 2019 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: IMMU shares over alleged securities laws.
- Benzinga•5 months ago
The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 25) Abbott Laboratories (NYSE: ABT ) Arena Pharmaceuticals, ...
